Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | PRKX | P51817 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | STK3 | Q13188 | 1/20 | 0.47 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7358627 | 0.98 | PARP1 (0.97) | PARP1PLK4MAPK13DYRK3ROCK2 | |
| Fumaric Acid SCHEMBL7358387 | 0.91 | PARP1 (0.82) | PARP1DHODH | |
| Benzimidazole SCHEMBL27528706 | 0.91 | PARP1 (0.82) | PARP1DHODH | |
| Citric Acid SCHEMBL7363546 | 0.84 | PARP1 (0.70) | PARP1DHODH | |
| SCHEMBL453514 | 0.84 | PARP1 (0.72) | PARP1DHODH | |
| SCHEMBL30225819 | 0.83 | PARP1 (0.68) | PARP1PKN1PKN2 | |
| Hydrochloric Acid SCHEMBL2129546 | 0.82 | PARP1 (0.70) | PARP1DHODH | |
| SCHEMBL112629 | 0.82 | PARP1 (0.70) | PARP1 | |
| Hydrochloric Acid SCHEMBL22165594 | 0.82 | PARP1 (0.70) | PARP1DHODH | |
| SCHEMBL9218238 | 0.82 | PARP1 (0.70) | PARP1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 472 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025042769-A1 | COMPOUNDS AND METHODS FOR INHIBITING POLY(ADP-RIBOSE) POLYMERASES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-02-27 | — | — | WO | claimed |
| CN-119303087-A | Preventive and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome | 日本新药株式会社 | 2025-01-14 | — | — | CN | claimed |
| CN-114867495-B | Preventive and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome | 日本新药株式会社 | 2024-10-18 | — | — | CN | claimed |
| US-20230040402-A1 | ANTITUMOR DRUG FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2023-02-09 | — | — | US | claimed |
| CN-114867495-A | Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome | 日本新药株式会社 | 2022-08-05 | — | — | CN | claimed |
| CN-114845735-A | Antitumor drug combined with immune checkpoint inhibitor | 日本新药株式会社 | 2022-08-02 | — | — | CN | claimed |
| EP-4003980-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Ribon Therapeutics Inc. (US) | 2022-06-01 | — | — | EP | claimed |
| WO-2021132473-A1 | ANTITUMOR DRUG FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR | 日本新薬株式会社 | 2021-07-01 | — | — | WO | claimed |
| WO-2021132472-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME | 日本新薬株式会社 | 2021-07-01 | — | — | WO | claimed |
| WO-2021021986-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | RIBON THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | claimed |
| EP-0841924-B1 | BENZIMIDAZOLE COMPOUNDS | UNIV NEWCASTLE VENTURES LTD (GB) | 2002-10-02 | — | — | EP | claimed |
| US-6310082-B1 | PHARMACEUTICAL COMPOSITION COMPRISING EFFECTIVE POLY(ADP-RIBOSE)POLYMERASE ENZYME INHIBITING AMOUNT OF BENZIMIDAZOLE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT AND/OR PRO-DRUG FORM THEREOF, WITH ACCEPTABLE CARRIER | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-30 | — | — | US | claimed |
| EP-1107966-A2 | OXO-PYRIDOIMIDAZOLE-CARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2001-06-20 | — | — | EP | claimed |
| EP-0656002-B1 | 3-OXO-PYRIDO(1,2-A -)BENZIMIDAZOLE-4-CARBOXYL AND 4-OXO-AZEPINO(1,2-A -)BENZIMIDAZOLE-5-CARBOXYL DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | MCNEILAB INC (US) | 2000-11-08 | — | — | EP | claimed |
| US-6100283-A | PRODRUG PHOSPHATE DERIVATIVE FOR POLY (ADP-RIBOSE) POLYMERASE ENZYME INHIBITOR FOR ADMINISTERING IN CONJUNCTION WITH ANTITUMOR DRUG OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2000-08-08 | — | — | US | claimed |
| WO-2000010973-A2 | OXO-PYRIDOIMIDAZOLE-CARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-03-02 | — | — | WO | claimed |
| EP-0841924-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-20 | — | — | EP | claimed |
| WO-1997004771-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1997-02-13 | — | — | WO | claimed |
| EP-0656002-A1 | 3-OXO-PYRIDO(1,2-A -)BENZIMIDAZOLE-4-CARBOXYL AND 4-OXO-AZEPINO(1,2-A -)BENZIMIDAZOLE-5-CARBOXYL DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | MCNEILAB, INC. (US) | 1995-06-07 | — | — | EP | claimed |
| WO-1994004532-A1 | 3-OXO-PYRIDO(1,2-A^_)BENZIMIDAZOLE-4-CARBOXYL AND 4-OXO-AZEPINO(1,2-A^_)BENZIMIDAZOLE-5-CARBOXYL DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | MCNEILAB, INC. (US) | 1994-03-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040402-A1 | ANTITUMOR DRUG FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR | MPEG1, CD274, PDCD1 | PARP1 492/4885PLK4 1242/4885MAPK13 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.